JP2005526024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526024A5 JP2005526024A5 JP2003565459A JP2003565459A JP2005526024A5 JP 2005526024 A5 JP2005526024 A5 JP 2005526024A5 JP 2003565459 A JP2003565459 A JP 2003565459A JP 2003565459 A JP2003565459 A JP 2003565459A JP 2005526024 A5 JP2005526024 A5 JP 2005526024A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- arylalkyl
- aryl
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003710 aryl alkyl group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102000003669 Antiporters Human genes 0.000 claims 1
- 108090000084 Antiporters Proteins 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35538902P | 2002-02-08 | 2002-02-08 | |
| PCT/US2003/004125 WO2003066035A2 (en) | 2002-02-08 | 2003-02-10 | Compounds for inhibiting insulin secretion and methods related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526024A JP2005526024A (ja) | 2005-09-02 |
| JP2005526024A5 true JP2005526024A5 (enExample) | 2006-03-23 |
Family
ID=27734511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565459A Pending JP2005526024A (ja) | 2002-02-08 | 2003-02-10 | インスリン分泌を阻害するための化合物及びそれに関連する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6958352B2 (enExample) |
| EP (1) | EP1472214A2 (enExample) |
| JP (1) | JP2005526024A (enExample) |
| AU (1) | AU2003210975A1 (enExample) |
| WO (1) | WO2003066035A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1291015A1 (en) * | 2001-09-10 | 2003-03-12 | Lunamed AG | Dosage forms having prolonged active ingredient release |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| AU2003248558B8 (en) * | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| US20060045912A1 (en) * | 2004-08-30 | 2006-03-02 | Peter Truog | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| EP1632245A1 (en) * | 2004-09-02 | 2006-03-08 | Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus | ICA512 couples insulin secretion and gene expression in Beta-cells |
| JP2010518171A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 非冠微小血管疾患の処置のためのラノラジンの使用 |
| CA2678272A1 (en) * | 2007-02-13 | 2008-10-02 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| EP2117549A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| CA2689633A1 (en) * | 2007-05-31 | 2008-12-11 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| US8172757B2 (en) * | 2007-06-18 | 2012-05-08 | Sunnybrook Health Sciences Centre | Methods and devices for image-guided manipulation or sensing or anatomic structures |
| US8791079B2 (en) | 2009-03-11 | 2014-07-29 | The Johns Hopkins University | Methods for treating heart failure by inhibiting the mitochondrial sodium-calcium exchanger (mNCE) |
| CA2903746C (en) | 2013-03-08 | 2022-08-23 | Amy Hauck Newman | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof |
| CN105218356B (zh) * | 2014-06-24 | 2020-01-21 | 中国科学院上海药物研究所 | PPARγ选择性调控剂及其制备方法和用途 |
| EP2985279B1 (en) | 2014-08-13 | 2017-08-02 | Red Bull GmbH | Heterocyclic compounds with working memory enhancing activity |
| WO2016023997A1 (en) | 2014-08-13 | 2016-02-18 | Red Bull Gmbh | Heterocyclic compounds with working memory enhancing activity |
| WO2019094856A1 (en) | 2017-11-13 | 2019-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Atypical inhibitors of monoamine transporters; method of making; and use thereof |
| EP3553053A1 (en) | 2018-04-12 | 2019-10-16 | Red Bull GmbH | (s)-enantiomeric form of a heterocyclic compound having motivation improving and/or reference memory enhancing activity |
| EP3792252A1 (en) | 2019-09-13 | 2021-03-17 | Red Bull GmbH | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances. |
| EP3929184A1 (en) | 2020-06-23 | 2021-12-29 | Red Bull GmbH | ((((3-halophenyl)(phenyl)methyl)sulfinyl)methyl)thiophene compounds and diastereomeric forms thereof for use in improving cognitive functions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8601585A (nl) * | 1986-06-19 | 1988-01-18 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | N-(2-gesubstitueerde alkyl)-n-imidazol-4-yl alkyl guanidine. |
| EP0467435A3 (en) * | 1990-07-19 | 1992-04-01 | Akzo N.V. | Benzhydryl derivatives having calmodulin inhibitor properties |
| WO2000071511A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| WO2002024204A2 (en) | 2000-09-20 | 2002-03-28 | Mitokor | Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
-
2003
- 2003-02-10 US US10/364,292 patent/US6958352B2/en not_active Expired - Fee Related
- 2003-02-10 AU AU2003210975A patent/AU2003210975A1/en not_active Abandoned
- 2003-02-10 WO PCT/US2003/004125 patent/WO2003066035A2/en not_active Ceased
- 2003-02-10 JP JP2003565459A patent/JP2005526024A/ja active Pending
- 2003-02-10 EP EP03737732A patent/EP1472214A2/en not_active Withdrawn
-
2005
- 2005-09-13 US US11/140,368 patent/US20060004062A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005501120A5 (enExample) | ||
| RU2207341C2 (ru) | Новые циклические соединения диамина, содержащие их лекарственные средства и способы лечения | |
| JP2006515858A5 (enExample) | ||
| IN2015DN01132A (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2015512860A5 (enExample) | ||
| JP2022520061A5 (enExample) | ||
| CA2503868A1 (en) | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors | |
| RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
| JP2004525179A5 (enExample) | ||
| NO20061788L (no) | HIV-replikasjonshemmede purinderivater | |
| JP2005530811A5 (enExample) | ||
| NO20072515L (no) | 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav | |
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| RU2005114021A (ru) | Производные имидазола и их применение в качестве периферически-селективных ингибиторов дофамин-бета-гидролазы | |
| JP2018531987A5 (enExample) | ||
| JP2006505543A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| NO20033145L (no) | Purinderivater som purinergiske reseptorantagonister | |
| JP2006519852A5 (enExample) | ||
| JP2003306481A5 (enExample) | ||
| JP2005517677A5 (enExample) | ||
| JP2008528624A5 (enExample) |